Regeneron Pharmaceuticals (REGN)

The sleeper story is Regeneron's complement franchise building a pipeline-in-a-bottle while everyone obsesses over DUPIXENT. George called C5 'a pipeline in a franchise' with customized approaches across multiple diseases - this could be multiple blockbusters, not just one program. The obvious headline is DUPIXENT hitting $20B annualized, but the real story is manufacturing vulnerability meeting biosimilar pressure on EYLEA. The binding constraint is supply chain fragility - Limerick disruption, EYLEA PFS delays, and looming biosimilar competition in H2. Most revealing quote: 'We decided to make Otarmeni free because it was the right thing to do' - signals confidence in pipeline depth but also acknowledgment of pricing pressure environment. My view changes if the Limerick facility faces another disruption or if EYLEA biosimilar penetration exceeds the 'mid-to-high teens' decline Marion warned about.